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The Ca2+-activated K+ channel, KCa3.1 (KCNN4/IK1/SK4), contributes to “classical,” pro-
inﬂammatory activation of microglia, and KCa3.1 blockers have improved the outcome
in several rodent models of CNS damage. For instance, blocking KCa3.1 with TRAM-34
rescued retinal ganglion neurons after optic nerve damage in vivo and, reduced p38 MAP
kinase activation, production of reactive oxygen and nitrogen species, and neurotoxicity by
microglia in vitro. In pursuing the therapeutic potential of KCa3.1 blockers, it is crucial to
assess KCa3.1 contributions to other microglial functions and activation states, especially
the IL-4-induced “alternative” activation state that can counteract pro-inﬂammatory states.
We recently found that IL-4 increases microglia migration – a crucial function in the
healthy and damaged CNS – and that KCa3.1 contributes to P2Y2 receptor-stimulated
migration. Here, we discovered that KCa3.1 is greatly increased in alternative-activated
rat microglia and then contributes to an enhanced migratory capacity. IL-4 up-regulated
KCNN4 mRNA (by 6 h) and greatly increased the KCa3.1 current by 1 day, and this required
de novo protein synthesis. The increase in current was sustained for at least 6 days. IL-4
increased microglial migration and this was reversed by blocking KCa3.1 with TRAM-34.
A panel of inhibitors of signal-transduction mediators was used to analyze contributions
of IL-4-related signaling pathways. Induction of KCNN4 mRNA and KCa3.1 current was
mediated speciﬁcally through IL-4 binding to the type I receptor and, surprisingly, it required
JAK3, Ras/MEK/ERK signaling and the transcription factor, activator protein-1, rather than
JAK2, STAT6, or phosphatidylinositol 3-kinase.The same receptor subtype and pathway
were required for the enhanced KCa3.1-dependent migration. In providing the ﬁrst direct
signaling link between an IL-4 receptor, expression and roles of an ion channel, this study
also highlights the potential importance of KCa3.1 in alternative-activated microglia.
Keywords: alternative microglial activation, AP-1 transcription factor, KCa3.1/SK4 channel, IL-4 signaling, M2
macrophage activation, microglial migration, Ras/MEK/ERK signaling, type I IL-4 receptor
INTRODUCTION
Following CNS injury, persistent inﬂammation can promote sec-
ondary tissue injury through excess production of reactive oxygen
and nitrogen species, cytokines,metalloproteases, and othermedi-
ators. Thus, it is important to limit the magnitude and duration of
the innate inﬂammatory response. In vitro studies of macrophages,
and more recently of microglia, show that IL-4 polarizes them to
an “alternative” activation state (or “M2”), while IL-10 and TGFβ
help resolve pro-inﬂammatory, “classical” activation (“M1”; Gor-
don, 2003; Colton, 2009; Varin and Gordon, 2009; Van Dyken
and Locksley, 2013). IL-4 binds to the IL-4 receptor α chain (IL-
4Rα) on type I and II receptors (Nelms et al., 1999; Van Dyken
and Locksley, 2013). The type II receptor can use IL-4 and IL-
13; whereas, the type I receptor uses IL-4 only, and it induces
larger changes in gene expression (Heller et al., 2008). Both recep-
tors initiate signaling cascades that alter gene expression and cell
behavior but the pathways differ. Type I receptors signal through
signal transducer and activator of transcription 6 (STAT6) and
insulin receptor substrate 2 (IRS2), while type II receptors only
signal through STAT6 (Sica and Mantovani, 2012; Van Dyken and
Locksley, 2013).
In a microarray analysis of IL-4 treated human macrophages
(Pello et al., 2012), we noted that KCNN4 mRNA was increased.
This was surprising because KCNN4 encodes the Ca2+-activated
K+ channel, KCa3.1 (IK1/SK4; Joiner et al., 1997; Khanna et al.,
1999), which we found is involved in several functions of classical-
activated rat microglia. That is, KCa3.1 blockers inhibited the
respiratory burst (Khanna et al., 2001), and LPS-induced p38
MAPK activation, NO production, and neurotoxicity (Kaushal
et al., 2007). In the latter study, LPS did not affect KCNN4 mRNA
expression at 24 h but the KCa3.1 current was not examined. Sev-
eral in vivo studies using the selective KCa3.1 blocker, TRAM-34,
show improved outcomes in rodent models of CNS conditions
with prominent inﬂammation; i.e., models of multiple sclero-
sis (Reich et al., 2005), optic nerve damage (Kaushal et al., 2007),
spinal cord injury (Bouhy et al., 2011), and ischemic stroke (Chen
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et al., 2011). BecauseKCa3.1 is now considered a therapeutic target
for reducing the pro-inﬂammatory state of the injuredCNS (Wulff
and Zhorov, 2008; Skaper, 2011; Maezawa et al., 2012), it is essen-
tial to determine its roles in other microglial activation states and
cell functions. One important microglial function is migration to
the damage site. We recently reported that blocking KCa3.1 with
TRAM-34 inhibits chemotactic migration of rat microglia follow-
ing P2Y2 purinergic receptor stimulation (Ferreira and Schlichter,
2013), and that IL-4-induced alternative activation increases the
microglial migratory capacity and range of enzymes used for
matrix degradation (Lively and Schlichter, 2013).
Therefore, we ﬁrst asked whether IL-4 up-regulates expression
of KCNN4 and the KCa3.1 current in rat microglia. Having found
this to be the case, we analyzed contributions of several effector
molecules downstream of the two subtypes of IL-4 receptor: JAK2,
JAK3, STAT6, phosphatidylinositol 3-kinase (PI3K),MEK, and the
transcription factor, AP1. Finally, we assessed the role of KCa3.1
and these signalingpathways in the increasedmigratory capacity of
IL-4-treated microglia. Together, our results indicate that the type
I IL-4 receptor, Ras/MEK/ERK pathway, and activator protein-1
(AP-1) are responsible for increasing KCNN4 expression, KCa3.1
current, and KCa3.1-dependent migratory capacity.
MATERIALS AND METHODS
PRIMARY RAT MICROGLIA CULTURES
All procedures on animalswere in accordancewith guidelines from
the Canadian Council on Animal Care and approved by the Uni-
versity Health Network Animal Care Committee. Microglia were
isolated from 1 to 2 day-old Sprague–Dawley rat pups (Charles
River, St. Constant, PQ, Canada) using our standard protocols,
which yield ≥99% microglia with little or no spontaneous activa-
tion (Sivagnanamet al., 2010; Liu et al., 2013; Lively and Schlichter,
2013; present study). Brieﬂy, after the meninges were removed,
the whole brain was minced, centrifuged (300 × g, 10 min),
re-suspended in Minimal Essential Medium (MEM; Invitrogen,
Carlsbad, CA, USA) supplemented with 10% fetal bovine serum
(FBS;Wisent, St-Bruno, PQ, Canada) and 0.05 mg/ml gentamycin
(Invitrogen), and seeded in tissue culture ﬂasks. Cells were then
cultured at 37◦C and 5% CO2 for 48 h, washed and cultured for
an additional 5–6 days. To separate the microglia from the bed of
astrocytes, the ﬂasks were shaken for 3–4 h (65 rpm, 37◦C, 5%
CO2), and the supernatant was centrifuged (300 × g, 10 min)
to spin down the microglia, which were then re-suspended in
MEM supplemented with 2% FBS, and plated at densities appro-
priate for each assay. For mRNA analysis and electrophysiology,
microglia were seeded at 1–2 million cells/35 mm culture dish
and 75,000 cells/coverslip, respectively, then grown for 1–2 days
before treatment with IL-4 or inhibitors. Similarly, for the pro-
liferation assay, cells were seeded at 10,000 cells/well of a 96-well
plate and grown for 18 h prior to treatments. For the migration
assay, microglia were seeded (30,000 cells/well) onto the inner
wells of TranswellTM chambers and allowed to settle for 1 h before
treatment.
CHEMICALS
To induce alternative activation, microglia were treated with rat
recombinant IL-4 (R&D Systems Inc., Minneapolis, MN,USA), as
before (Liu et al., 2013; Lively and Schlichter, 2013). The JAK2/3
inhibitor,AG490 (EMDMillipore, Toronto,ON,Canada)was used
at 10 μM, a concentration previously shown to inhibit JAK sig-
naling in primary microglia (Kim et al., 2002; Huang et al., 2008).
The JAK2-selective inhibitor, TG101348 (Selleckchem, Houston,
TX, USA; IC50 = 3 nM) and JAK 3-selective inhibitor, tofac-
itinib (Selleckchem; IC50 = 1 nM) were used at 30 nM and
10nM,respectively. STAT6was inhibited using 200nMAS1517499
(IC50 = 21 nM; Axon Medchem BV, Groningen, Netherlands).
100 nM wortmannin (EMD Millipore; IC50 = 5 nM) was used to
inhibit PI3K activity. The mitogen-activated protein kinase kinase
(MAPKK, also known as MEK) inhibitors, U0126 (IC50 = 72 nM
for MEK1, 58 nM for MEK2) and PD098059 (IC50 = 2–7 μM)
were obtained from Sigma–Aldrich (Oakville, ON, Canada), and
used at 10 μM and 20 μM, respectively. AP-1 is a c-Fos/c-Jun
heterodimer that can bind to the KCNN4 promoter and initi-
ate transcription in activated T lymphocytes (Ghanshani et al.,
2000). To inhibit AP-1, the retinoid, SR11302 (R&D Systems)
was used at 1 μM; a concentration shown to inhibit AP-1 activ-
ity (Hu et al., 2009). To inhibit protein synthesis, cycloheximide
(CHX; Sigma) was used at 10 nM, a concentration that is effec-
tive in primary microglia (Chen et al., 2009). TRAM-34 (Sigma)
was used at 1 μM to selectively block KCa3.1 (IC50 = 25 nM;
Wulff et al., 2000). All inhibitors were diluted in DMSO. None of
the compounds were toxic to rat microglia at the concentrations
used. The KCa channel activators, riluzole, 1-EBIO, and NS309
(all from Sigma), were used at 300 μM, 300 μM, and 500 nM,
respectively.
MULTIPLEXED GENE EXPRESSION ANALYSIS (NanoString nCounterTM)
This high-throughput method has similar sensitivity to real-time
qRT-PCR but can analyze expression of many genes using a sin-
gle RNA sample (Geiss et al., 2008). Total RNA was extracted
as previously described (Sivagnanam et al., 2010; Liu et al., 2013;
Lively and Schlichter, 2013) using TRIzol reagent (Invitrogen), fol-
lowed by RNeasy Mini Kit (QIAGEN, Mississauga, ON, Canada)
for further puriﬁcation. RNA samples were stored at –80◦C.
Genes analyzed in this study were chosen based on previous
reports of their increased expression following IL-4 treatment
(either from our lab or reported in the literature) as well as
genes of special relevance to this study (e.g., KCNN4). Each
gene was recognized by a probe set that was designed and syn-
thesized by NanoString nCounterTM technologies (Table 1). A
probe set consists of capture and reporter probes, which are
complimentary sequences of 35–50 base pairs that are designed
to bind speciﬁcally to the mRNA of interest. The capture
probe also contains a short sequence linked to biotin, while the
reporter probe is coupled to a unique color-coded tag used for
detection.
For both IL-4-treated microglia and corresponding control
(unstimulated) microglia, samples were harvested from sepa-
rate cultures isolated from individual rat pups (n = 5 pups).
We then supplied 200 ng of extracted RNA from unstimulated
and IL-4-treated cultures to the Princess Margaret Genomics
Centre, Toronto, Canada1, which conducted the NanoString
1http://www.pmgenomics.ca
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Table 1 |Target sequences used to design probe sets for multiplexed gene expression analysis (NanoString nCounterTM).
Gene Genbank Accession # Target sequence
CD163 NM_001107887.1 AGTTTCCTCAAGAGGAGAGGTCTTGATACATCAAGTTCAGTACCAAGAGATGGATTCGAAGACGGATGATCTGGACTTGCT
GAAATCCTCGGGTTGGCAT
HPRT1 NM_012583.2 AGCTTCCTCCTCAGACCGCTTTTCCCGCGAGCCGACCGGTTCTGTCATGTCGACCCTCAGTCCCAGCGTCGTGATTAGTG
ATGATGAACCAGGTTATGAC
IL-4Rα NM_133380.2 GGGTGTCAGCATCTCCTGCATCTGCATCCTATTGTTTTGCCTGACCTGTTACTTCAGCATTATCAAGATTAAGAAGATATGGT
GGGACCAGATTCCCACT
KCNN4 NM_023021.1 ATCGGACTCATGGTGCTGCACGCTGAGATGTTGTGGTTCCTGGGTTGCAAGTGGGTGCTGTACCTGCTCTTGGTTAAGTG
TTTAATCACGCTGTCCACTG
MRC1 NM_001106123.1 CTTTGGAATCAAGGGCACAGAGCTATATTTTAACTATGGCAACAGGCAAGAAAAGAATATCAAGCTTTACAAAGGTTCCGG
TTTGTGGAGCAGATGGAAG
STAT6 NM_001044250.1 GTGGTTTGATGGTGTCCTGGACCTCACTAAACGCTGTCTTCGGAGCTACTGGTCAGATCGGCTGATCATCGGCTTTATCAG
TAAGCAATATGTCACTAGC
nCounterTM analysis. Prior to running the analysis, samples
were assessed for purity using Nanodrop 1000. Data were nor-
malized to expression of the housekeeping gene, hypoxanthine
guanine phosphoribosyl transferase (HPRT1),which we ﬁnd to
be especially stable in primary rat microglia under all treat-
ments we have investigated (Sivagnanam et al., 2010; Liu et al.,
2013; Lively and Schlichter, 2013). Sample preparation, hybridiza-
tion, detection, and scanning were executed following NanoString
Technologies’ recommendations. mRNA transcripts were ana-
lyzed and quantiﬁed using the nCounterTM digital analyzer
software2.
QUANTITATIVE REAL-TIME REVERSE-TRANSCRIPTASE POLYMERASE
CHAIN REACTION (qRT-PCR)
RNA was extracted as described above. The follow-
ing primers for KCNN4 and the housekeeping gene,
HPRT1, were designed using “Primer3Output”3. KCNN4:
forward (5′-GCTGGAGCAGGAGAAGAGG-3′) and reverse
(5′-AAAGGAGGAAGGCAGTGGA-3′). HPRT1: forward (5′-
CAGTACAGCCCCAAAATGGT-3′) and reverse (5′-CAAGGGC-
ATATCCAACAACA-3′). cDNA was ﬁrst synthesized by reverse
transcription according to the manufacturer’s instructions (Invit-
rogen). In brief, 0.8 μg of total RNA was reverse transcribed in
20 μl volume using 200 U of SuperScriptII RNase reverse tran-
scriptase, with 0.5 mM dNTPs and 0.5 μM oligo dT (Invitrogen).
Using anABI PRISM 7700 Sequence Detection System (PE Biosys-
tems, Foster City, CA, USA), ampliﬁcation was then performed as
follows: (1) 50◦C for 2 min, (2) 95◦C for 10 min, (3) 40 cycles
at 95◦C for 15 s and 60◦C for 60 s, and (4) a dissociation step
(95◦C for 15 s, 60◦C for 15 s, 95◦C for 15 s). “No-template” and
“no-ampliﬁcation” controls were included for each gene. Speciﬁc
ampliﬁcation was conﬁrmed by the single peak on melt curves.
The threshold cycle (CT) for KCNN4 was normalized to that of
HPRT1.
2http://www.nanostring.com/support/ncounter/
3http://bioinfo.ut.ee/primer3-0.4.0
MICROGLIA STAINING
Rat microglia were seeded at ∼6 × 104 cells/15 mm diameter cov-
erslip, cultured for 1 day in 2% FBS, and then stimulated with
20 ng/ml rat recombinant IL-4. Cells were ﬁxed 24 h later in 4%
paraformaldehyde (Electron Microscopy Sciences, Hatﬁeld, PA,
USA) at room temperature for 10 min and then permeabilized
with 0.2% Triton X-100 for 5 min. To examine morphology as
a function of activation state, microglia were stained with FITC-
conjugated tomato lectin (TL; 1:500, 15 min; Sigma) and coun-
terstained with the nuclear dye, 4′,6-diamidino-2-phenylindole
(DAPI; 1:3000 in PBS, 5 min; Invitrogen).
PATCH-CLAMP ELECTROPHYSIOLOGY
Primary rat microglia were plated on 15 mm diameter coverslips
(∼7.5 × 104/coverslip), and mounted in a model RC-25 perfusion
chamber (Warner Instruments, Hamden, CT) for patch clamp
recordings. The cells were superfused with an extracellular (bath)
solution containing (in mM): 125 NaCl, 5 KCl, 1 MgCl2, 1 CaCl2,
5 glucose, and 10 HEPES, adjusted to pH 7.4 (with NaOH) and to
∼300 mOsm with sucrose. Bath solutions were exchanged using
a gravity-driven perfusion system ﬂowing at 1.5–2 ml/min and all
recordingsweremade at room temperature.Whole-cell recordings
were made with pipettes pulled from thin-walled borosilicate glass
(WPI, Sarasota, FL) using a Narishige puller (Narishige Scientiﬁc,
Setagaya-Ku, Tokyo) to a resistance of 6−9 M, which provided
good seal stability. Pipettes were ﬁlled with a solution containing
(in mM): 100 K-aspartate, 40 KCl, 1 MgCl2, 2 MgATP, 5 EGTA, 4.3
CaCl2, 10 HEPES, pH adjusted to 7.2 with KOH, 280 mOsm/kg
H2O. This intracellular solution had 1.0 μM free Ca2+, as calcu-
lated with WEBMAXC Extended software4, which was expected
to facilitate KCa3.1 channel activation. However, as described in
the Results, it was necessary to also add a KCa channel activator.
Recordings were made with an Axon Multiclamp 700A ampliﬁer
(Molecular Devices, Sunnyvale, CA, USA), and compensated on-
line to minimize the capacitance transient, which can be large due
4http://www.stanford.edu/∼cpatton/webmaxc/webmaxcE.htm
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to the high membrane resistance, up to several gigaohms (Newell
and Schlichter, 2005). Patch-clamp data were ﬁltered at 5 kHz,
and acquired and digitized using a Digidata 1322A board with
pClamp software (Molecular Devices, Sunnyvale, CA, USA). The
junction potential was reduced by using agar bridges made with
bath solution, and was about –5 mV, as calculated using the utility
in pClamp.
MIGRATION ASSAY
Microglia were seeded on ﬁlters with 8 μm-diameter pores placed
in TranswellTM chambers (VWR). After 30 min, MEM supple-
mented with 2% FBS was added to the upper and lower wells.
After 1 h, microglia were left unstimulated (controls) or incubated
with 20 ng/ml IL-4, with or without one of the following com-
pounds: 1 μM TRAM-34, 10 nM cycloheximide, 10 μM AG490,
10 nM tofacitinib, 30 nM TG101348, 200 nM AS1517499, 100 nM
wortmannin, 20 μM PD098059, 10 μM U0126, or 1 μM SR11302.
After incubating for 24 h (37◦C, 5% CO2), microglia on the ﬁl-
ters were ﬁxed in 4% paraformaldehyde for 10 min and washed
with PBS. To remove the remaining cells that had not migrated
through the ﬁlter, the upper side of the ﬁlter was swirled with
a Q-tip. Cells that migrated to the underside of the ﬁlters were
visualized by adding 0.3% crystal violet for 1 min, followed by
a quick wash in PBS to remove free dye. Migrated cells were
counted (ﬁve random ﬁelds/ﬁlter) at 20× magniﬁcation using an
Olympus CK2 inverted microscope (Olympus, Tokyo, Japan). For
each culture, total cell counts obtained from experimental Tran-
swell chambers (IL-4 treated ± an antagonist) were normalized to
the total cell counts from corresponding unstimulated (control)
Transwells.
CELL PROLIFERATION ASSAY
The CyQUANT NF cell proliferation assay (Invitrogen) was used
to measure cell proliferation. Microglia were seeded at 103/well
on a 96-well ﬂat-bottom plate. To generate a standard curve of
ﬂuorescence intensity versus cell number, we added a range of
0–30,000 cells in separate wells. Cells were incubated overnight
(37◦C, 5% CO2) in MEM supplemented with 2% FBS. The fol-
lowing morning, 20 ng/ml IL-4, 1 μM TRAM-34 or both were
added to test wells, incubated for a further 24 h, and then the
CyQUANT assay was performed according to the manufacturer’s
protocol. In brief, after 30min incubation in the dye-binding solu-
tion (37◦C, 5% CO2), ﬂuorescence intensity was measured using
a multi-label plate counter (Victor3 1420, Perkin Elmer, Wood-
bridge, ON, Canada). Excitation was set at 485 nm and emission
was measured at 535 nm, with 0.1 s readings at 3 mm from the
bottom of the plate taken in triplicate. For treatment samples,
cell numbers were calculated by interpolation from the standard
curve.
STATISTICAL ANALYSIS
All graphical data are expressed as mean ± SEM. Changes in
gene expression from NanoString were analyzed using a 2-way
ANOVA with Bonferroni’s post hoc test; the two independent vari-
ables were time and stimulation (untreated versus IL-4 treated).
For analyzing migration and proliferation data, a 2-way ANOVA
followed by Bonferroni’s test was used to determine the effects
of stimulation and multiple inhibitors. When only one variable
was involved, Student’s unpaired t-test was used; i.e., when assess-
ing effects of stimulation alone (untreated versus IL-4 treated)
on KCa3.1 current amplitude or KCNN4 mRNA expression (qRT-
PCR) at a single time.Whenanalyzing effects ofmultiple inhibitors
on a single outcome (KCa3.1 current, KCNN4 mRNA, migra-
tion), a 1-way ANOVA with Tukey’s post hoc test was used. All
analyses were conducted using GraphPad Prism ver 5.01 (San
Diego, CA, USA). Values of p < 0.05 were taken as statistically
signiﬁcant.
RESULTS
IL-4-INDUCED ALTERNATIVE ACTIVATION EVOKES PROLONGED
UP-REGULATION OF KCNN4 EXPRESSION AND KCa3.1 CURRENT
mRNA expression
It is well known that IL-4 evokes alternative activation of microglia
(Colton et al., 2006; Colton, 2009), as we recently showed for rat
microglia at 24 h after IL-4 treatment (Liu et al., 2013; Lively and
Schlichter, 2013). Here, we show increased expression of several
prototypical alternative activation genes as early as 6 h after treat-
ment with 20 ng/ml of rat recombinant IL-4 (Figure 1A). Com-
pared with time-matched unstimulated microglia, the increases
at 6 and 24 h were 6.5- and 5.3-fold for the C-type man-
nose receptor 1 (MRC1), 4.2- and 2.5-fold for the IL-4Rα, 3.9-
and 1.8-fold for arginase 1 (Arg1), and 10.8- and 5.0-fold for
CD163. In addition, STAT6 – a primary transcription factor
downstream of IL-4 receptors (reviewed in Sica and Mantovani,
2012) – was increased by 1.6- and 2.4-fold at 6 and 24 h, respec-
tively (Figure 1B). IL-4 treatment also increased KCNN4, which
encodes the intermediate conductance, Ca2+-activated K+ chan-
nel, KCa3.1 (see Introduction), by 2.9-fold at 6 h and 4.2-fold at
24 h (Figure 1C).
KCa3.1 current
Whole-cell currents were compared between unstimulated
microglia and cells treated for 24 h with IL-4. The KCa3.1
current was quantiﬁed as the component blocked by 1 μM
TRAM-34 (Wulff et al., 2000), a procedure that eliminated the
inward-rectiﬁer (Kir2.1) current that is prevalent at negative
membrane potentials and the depolarization-activated outward
Kv1.3 current (Schlichter et al., 1996; Kotecha and Schlichter,
1999; Fordyce et al., 2005; Newell and Schlichter, 2005). For
each cell, repeated voltage ramps were applied to examine
current-versus-voltage (I–V) relations, and to quantify the cur-
rent amplitude and prevalence (proportion of cells expressing the
current).
(i) Unstimulated microglia. Attempts to activate the current
by simply elevating intracellular (pipette) Ca2+ to 1 μM were
unsuccessful (>50 cells tested), despite allowing the cytosol to
equilibrate with the pipette solution for up to 10 min (∼10 cells).
This lack of current activation is consistent with our recent study
of the MLS-9 microglia cell line using pipettes of a similar resis-
tance (4−7 M), in which a KCa3.1 current was activated by
1 μM Ca2+ in only 1/10 cells (Liu et al., 2013). We found that
the pipette solution diffuses into microglial cells within 1 min
after break-in, as judged by the reporter dye, Ca-Green (molecu-
lar weight: 1.14 kDa). Next, we bath applied three well-established
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FIGURE 1 | IL-4 treatment induces alternative activation, and
up-regulates IL-4 signaling genes and KCNN4 mRNA. (A)Treating rat
microglia with rat recombinant IL-4 (20 ng/ml; 6 or 24 h) up-regulated
expression of “alternative” activation markers: C-type mannose receptor 1
(MRC1), IL-4 receptor α subunit (IL-4Rα), CD163 and arginase 1 (Arg1).
(B,C) Also up-regulated were “signal transducer and activator of
transcription 6” (STAT6), a transcription factor involved in the IL-4 signaling
pathway; and the Ca2+-activated K+ channel, KCNN4. Gene expression
was analyzed using NanoString and normalized to the housekeeping gene,
HPRT1. Values are expressed as mean ± SEM for ﬁve replicates from
different cell cultures. Two-way ANOVA with Bonferroni’s post hoc test
revealed differences between unstimulated and IL-4-treated microglia (∗)
and some time-dependent changes (#). One symbol indicates p < 0.05,
two symbols, p < 0.01, three symbols, p < 0.001.
KCa channel activators: riluzole (300μM),which reliably activated
KCa3.1 in MLS-9 cells (Liu et al., 2013), 1-EBIO (300 μM), and its
more potent derivative, NS309 (500 nM; Wulff et al., 2007). Ele-
vated intracellular Ca2+alone did not activate a current (0/19 cells;
example traces labeled “1” in Figures 2A,B). The KCa activators
evoked little or no current (traces labeled “2”). A small current
(<100 pA) was seen in only 1/4 cells with riluzole (Figure 2A),
3/10 cells with NS309 (Figure 2B; example showing the largest
responder), and 1/5 cells with 1-EBIO (not illustrated). Not sur-
prisingly, TRAM-34 had little or no effect in control microglia
(traces labeled “3”).
(ii) IL-4-treated microglia. With 1 μM intracellular Ca2+ alone
(traces labeled “1”), there was very little current between –80
and –20 mV, but a variable-amplitude depolarization-activated
Kv1.3 current was often seen as an inﬂection in the I–V relation.
[The Kv1.3 current showed considerable variability (even in con-
trol cells; compare Figures 2A,B), and the effects of microglial
activation state will be examined in a future study.] Most impor-
tantly for the present study, all three KCa activators evoked large
FIGURE 2 | IL-4 treatment induces a robust KCa3.1 current.
(A,B) Representative currents in response to repeated voltage ramps from
–100 to +80 mV from a holding potential of –70 mV. Unstimulated microglia
(left panels) were compared with cells treated for 24 h with 20 ng/ml of IL-4
(right panels). Each example shows superimposed currents in normal bath
solution (traces labeled “1”), after adding a KCa channel activator (300 μM
riluzole or 500 nM NS309; traces labeled “2”), and after adding the
selective KCa3.1 blocker, 1 μMTRAM-34, in the continued presence of the
channel activator (blue traces labeled “3”). (C) An example of the time
course of current activation by NS309 (measured at +80 mV; same
IL-4-treated cell as B) and block by 1 μMTRAM-34. (D) A scatterplot of the
TRAM-34-sensitive KCa3.1 component in each unstimulated and
IL-4-treated microglial cell summarizes the KCa3.1 current density (pA/pF)
and prevalence (proportion of cells expressing KCa3.1 current). Dashed
lines indicate mean current densities (note differences in theY-axis scales).
Statistical differences between control (unstimulated) and IL-4-treated
microglia were determined by an unpaired t -test for each of the activators:
###p < 0.001.
currents (traces labeled “2”). As is diagnostic of KCa3.1, the cur-
rent was present at all voltages tested (−100 to +80 mV), reversed
near the K+ Nernst potential, and was substantially blocked (aver-
age of 95%, n = 14) by 1 μM TRAM-34 (traces labeled “3”).
[The current with riluzole+TRAM-34 (Figure 2A, trace “3”) was
smaller than the control (trace “1”) because riluzole also inhibits
Kv1.3 (Bellingham, 2011).] An example of the time course of cur-
rent activation by NS309 and block by TRAM-34 is shown in
Figure 2C. KCa3.1 currents were evoked by riluzole in 4/4 cells,
by NS309 in 8/9 cells, and by 1-EBIO in 5/5 cells (not illus-
trated). The mean amplitude of the TRAM-34-sensitive current
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(i.e., trace 2 minus trace 3) was compared between unstimu-
lated and IL-4-treated microglia (Figure 2D). Riluzole-evoked
KCa3.1 currents were 0.7 ± 0.7 pA/pF in unstimulated microglia
versus 14.6 ± 1.9 pA/pF in IL-4-treated cells (n = 4 each).
NS309-evoked currents were 1.7 ± 0.9 pA/pF in unstimulated
(n = 10) versus 38.9 ± 8.8 pA/pF in IL-4-treated microglia
(n = 9). 1-EBIO-evoked currents were 0.8 ± 0.8 pA/pF in
unstimulated versus 22.9 ± 5.4 pA/pF in IL-4-treated cells
(n = 5 each; data not illustrated). [A similar current was
evoked by the activators in >50 other IL-4-treated microglia,
but TRAM-34 was not added to quantify the KCa3.1 compo-
nent.] Riluzole, NS309, and 1-EBIO are known to also activate
KCa2.3 channels with approximately ﬁve-fold lower potency
(Wulff and Zhorov, 2008); and although not investigated fur-
ther in the present study, a small KCa current remained in
the presence of 1 μM TRAM-34 in 6/14 microglia. All subse-
quent experiments used NS309 (500 nM), which has an EC50 of
∼30 nM for activating KCa3.1 (Strobaek et al., 2004; Wulff et al.,
2007).
(iii) LPS-treated microglia. As noted in the Introduction,
KCa3.1 channels are involved in classical activation of ratmicroglia
but 24 h LPS treatment did not alter KCNN4 expression (Kaushal
et al., 2007). The purpose of the present study was to com-
pare unstimulated and alternative-activatedmicroglia, and further
studies will be needed to investigate classical activation evoked by
other stimuli. Here, we found that at 24 h after LPS treatment,
the KCa3.1 current amplitude and prevalence were not obvi-
ously changed. Relatively small KCa3.1 currents were seen in 3/9
microglia, and the mean NS309-evoked current of the respond-
ing cells was 3.6 ± 1.5 pA/pF (n = 3). This observation does not
rule out the possibility that the current can be activated by other
stimuli or at other times after LPS treatment.
Time course of KCa3.1 current induction and need for protein
synthesis
We recently showed that a unipolar morphology with a large
lamellum at the leading edge and a trailing uropod is charac-
teristic of migrating rat microglia (Siddiqui et al., 2012; Vincent
et al., 2012), and found that IL-4 treatment increases their migra-
tory capacity (Lively and Schlichter, 2013). Here, we examined
the microglia morphology at 1 and 6 days with and without
IL-4 treatment and quantiﬁed the KCa3.1 current over the ﬁrst
6 days after IL-4 (Figure 3). At 1 and 6 days, most unstimulated
microglia were unipolar with a lamellum and uropod that are
evident in the higher-magniﬁcation insets; the remainder were
bipolar. Similarly, at both times, most IL-4-treated microglia
were unipolar with a lamellum and uropod, although the lamel-
lum was often smaller and more rufﬂed than in unstimulated
cells. Thus, cell size and morphology were not indicators of
the changes in KCNN4 expression and KCa3.1 current in the
alternative-activation state. For consistency in quantifying the
KCa3.1 current over time, patch-clamp recordingswere conducted
on unipolar microglia with a distinct lamellum and a uropod,
and all currents were normalized to the cell size (capacitance
in pF). As summarized in Figure 3B, robust TRAM-34-sensitive
KCa3.1 currents were reliably evoked by NS309 in IL-4-treated
cells, and were present on all days tested (1−6 days). This
induction of current was paralleled by increases in KCNN4 expres-
sion, which increased ∼10-fold at 1 day and ∼8-fold at 6 days
(Figure 3C). At 1 day (Figure 2D) and 6 days after IL-4 treat-
ment (Figure 3D), the NS309-evoked current was substantially
blocked by TRAM-34. We found that de novo synthesis of KCa3.1
protein was required for induction of the KCa3.1 current. That
is, in microglia that were treated for 24 h with IL-4 and the
protein synthesis inhibitor, cycloheximide, the current was 84%
smaller (4.7 ± 1.5 pA/pF) than in IL-4-treated control cells
(29.0 ± 8.1 pA/pF; Figure 3E).
UP-REGULATION OF KCNN4 and KCa3.1 CURRENT IS MEDIATED BY THE
TYPE I IL-4 RECEPTOR, AND REQUIRES Ras/MEK/ERK AND AP-1
SIGNALING
The next goal was to determine which IL-4 receptor and signal-
ing pathway was responsible for the increase in KCNN4 mRNA
and KCa3.1 current. To simplify the explanation of the exper-
iments and results, Figure 4 shows known signaling pathways
downstream of type I and II IL-4 receptors and the molecules
we found to affect KCNN4 expression and KCa3.1 current. [Note:
The ﬁgure legend deﬁnes the signaling molecules, inhibitor names
and their targets.] Type II receptors interact with JAK1 and JAK2,
and signal through STAT6 only. Type I receptors interact with
JAK1 and JAK3, and their downstream signaling is usually through
two pathways; i.e., one mediated by STAT6, and one by IRS2
and PI3K (Heller et al., 2008). Less commonly observed is that
IRS2 can recruit the Grb2 adaptor protein, which associates with
SOS and activates downstream Ras/MAP kinase pathways (p38,
JNK, ERK1/2; Jiang et al., 2000; Wills-Karp and Finkelman, 2008).
While use of the latter pathway apparently depends on cell type,
IL-4 does activate it in keratinocytes (Wery-Zennaro et al., 2000)
and in T- and pro-B-lymphocyte cell lines (Hunt et al., 2002;
Canﬁeld et al., 2005). Activated ERK1/2 then translocates to the
nucleus and can activate the transcription factor, AP-1 (c-Fos/c-
Jun heterodimer; Park and Levitt, 1993; Marais and Marshall,
1996). We used inhibitors of JAK2 and JAK3 to parse out the
receptor type, and inhibitors of STAT6, PI3K, MEK, and AP-1
to assess downstream pathways. Their effects on expression of
KCNN4 mRNA and KCa3.1 current will next be described in
detail.
Janus kinases: JAK2 and JAK3
KCNN4 expression (Figure 5A) and KCa3.1 current density
(Figure 5B) were quantiﬁed in cells treated for 24 h with IL-
4 with or without a JAK inhibitor. KCNN4 expression was
reduced 34% by the JAK2/3 inhibitor, AG490. This regulation
is due to JAK3 because the selective JAK3 inhibitor, tofaci-
tinib, reduced the transcript level by 36%, while the selective
JAK2 inhibitor, TG101348, did not. [The possible increase in
KCNN4 by TG101348 did not reach statistical signiﬁcance.] The
same pattern of drug sensitivity was seen for the KCa3.1 current
but the effects were greater. The summarized current densi-
ties (Figure 5B) and representative KCa3.1 current traces and
time-courses (Figures 5C–E) show that AG490 reduced the cur-
rent density by 90% (from 38.9 ± 8.3 to 4.0 ± 1.0 pA/pF),
tofacitinib reduced it by 92% (to 3.7 ± 1.7 pA/pF), and with
TG101348, the current remained at 29.5 ± 6.9 pA/pF. By
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FIGURE 3 | KCa3.1 current by IL-4 remains elevated over time and
requires de novo protein synthesis. (A) Effect of IL-4 treatment on
microglial morphology. Primary rat microglia were treated with 20 ng/ml
IL-4, ﬁxed 1 or 6 days later, and stained with tomato lectin (green) to
identify microglia and DAPI (blue) to label nuclei. Scale bars = 100 μm
(main images) and 50 μm (insets). (B) Microglia were treated with 20 ng/ml
IL-4, and patch clamp experiments were performed from 1 to 6 days later.
In all experiments, KCa3.1 currents were evoked by NS309 and blocked
with TRAM-34. TRAM-34-sensitive KCa3.1 current densities (pA/pF;
mean ± SEM for the number of cells indicated) were compared at each
time point in control (unstimulated) microglia versus IL-4 treated cells.
[Note: For unstimulated cells, error bars were often smaller than the
symbol.] Statistical differences at each time point were determined using
unpaired t -tests, and indicated as #p < 0.05, ##p < 0.01, ###p < 0.001.
(C) Quantitative real-time qRT-PCR showed a 10-fold increase in KCNN4
transcript levels at 1 day and an eightfold increase at 6 days following IL-4
treatment compared with unstimulated cells. Values are expressed as
mean ± SEM. The number of individual cultures was 6 each for 1 day
control and IL-4, 3 for 6 day control and 5 for 6 day IL-4. An unpaired t -test
was used to determine differences between unstimulated and IL-4-treated
microglia: **p < 0.01, ***p < 0.001. (D) A representative recording at
6 days after IL-4 treatment shows currents evoked by voltage ramps from
–100 to +80 mV (holding potential, –70 mV) with control bath solution
(trace “1”), after adding NS309 (trace “2”), and 1 μMTRAM-34 (trace “3”).
The time-course shows current activation (measured at +80 mV) and its
block by 1 μMTRAM-34. (E) To assess the need for protein synthesis,
microglia were cultured for 24 h with 20 ng/ml IL-4 with or without 10 nM
cycloheximide (CHX). The representative recording (same protocol as D)
shows a cycloheximide-treated cell (left panel) with control bath solution
(trace “1”), after adding NS309 (trace “2”), and 1 μMTRAM-34 (trace “3”),
and the time course (right panel) measured at +80 mV. Inset: Summary of
the TRAM-34-sensitive KCa3.1 current density for microglia treated with IL-4
alone or with IL-4+CHX. Statistical differences were determined by an
unpaired t -test; ##p < 0.01.
implicating JAK3, these results show that the type I IL-4 recep-
tor is involved in up-regulating KCNN4 mRNA and KCa3.1
current.
STAT6, PI3K, MEK, and AP-1
KCNN4 expression (Figure 6A) and KCa3.1 current density
(Figure 6B) were quantiﬁed after IL-4 treatment, with or without
a STAT6 inhibitor (AS1517499), PI3K inhibitor (wortmannin),
MEK inhibitor (PD98059) or AP-1 inhibitor (SR11302). We had
anticipated that KCNN4 induction would require STAT6 or PI3K
but surprisingly, inhibiting either one increased KCNN4 in IL-4-
treated cells: by 60% for AS1517499 and 50% for wortmannin
(Figure 6A). The MEK inhibitor, which was used to assess
involvement of the Ras/Raf/MEK pathway, reduced KCNN4 to
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FIGURE 4 | Schematic diagram depicting known IL-4 signaling pathways
and the outcomes observed.The initial step is IL-4 binding to the IL-4
receptor α subunit (IL-4Rα), which can then heterodimerize with either the
common gamma chain (γC) to form the type I receptor or with IL-13Rα1
(which binds IL-13) to form the type II receptor. Heterodimerization of either
receptor subtype activates JAKs but the speciﬁc JAK depends on the receptor
subunit composition. JAK1 associates with IL-4Rα, and is thus common to
both receptor subtypes. JAK3 associates with γC of the type I receptor, and
JAK2 associates with IL-13Rα1 of the type II receptor. For both receptor
subtypes, activated JAKs phosphorylate tyrosine residues on IL-4Rα, which
then act as docking sites for signaling molecules (i.e., STAT6, IRS2) that are
then phosphorylated. Phosphorylated STAT6 dimerizes and translocates to
the nucleus where it acts as a transcription factor, binding to the promoter of
IL-4 (and IL-13) responsive genes. Recruitment of IRS2 is speciﬁc to the type I
receptor, and activates downstream PI3K and Grb2 signal cascades which,
like STAT6, change gene expression through the transcription factor, AP-1.
(For more details on IL-4 signal transduction, see Kelly-Welch et al., 2003;
Zamorano et al., 2003; Oh et al., 2010.) AP-1, activator protein-1; Grb2, growth
factor receptor-bound protein 2; IL-4, interleukin 4; IL-13, interleukin-13; IRS2,
insulin receptor substrate 2; JAK, Janus kinase; PI3K, phosphatidylinositol
3-kinase; STAT6, signal transducer and activator of transcription 6. Inhibitors
used: 1 μM SR11302 for AP-1; 10 μM AG490 for JAK2/3; 30 nMTG101348 for
JAK2; 10 nM tofacitinib for JAK3; 20 μM PD098059 or 10 μM U0126 for
MEK1/2; 100 nM wortmannin for PI3K; 200 nM AS1517499 for STAT6.
nearly the level of unstimulated microglia (without IL-4). Con-
sistent with a role for the MEK/ERK pathway, inhibiting the
transcription factor, AP-1, reduced KCNN4 expression by 40%.
There were similarities and differences in effects of these inhibitors
on the KCa3.1 current in IL-4-treated microglia. Summarized
current densities (Figure 6B), and representative current traces
and time courses (Figures 6C–F), show that the MEK inhibitor
reduced the current by 83% (to 5.8 ± 2.3 pA/pF) but the STAT6
inhibitor did not reduce it. [The MEK inhibitor, U0126, simi-
larly reduced KCNN4 and KCa3.1 current (data not shown)]. The
AP-1 inhibitor reduced the KCa3.1 current density by 69% (from
34.9 ± 4.4 to 7.4 ± 2.5 pA/pF). Surprisingly, the PI3K inhibitor
reduced the current by 43%; from 34.9 ± 4.4 to 20.0 ± 3.2 pA/pF.
Together, these results suggest that the elevated KCNN4 expression
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FIGURE 5 | JAK3 is required for induction of KCNN4 mRNA and KCa3.1
current in IL-4 treated microglia. Rat microglia were treated for 24 h with
20 ng/ml rat recombinant IL-4 without (control) or with a JAK inhibitor: 10 μM
AG490 (for JAK2/3), 10 nM tofacitinib (for JAK3), or 30 nMTG101348 (for
JAK2). (A) IL-4-mediated induction of KCNN4 mRNA was examined using
quantitative real-time qRT-PCR. Control KCNN4 mRNA levels in unstimulated
microglia (no IL-4) are indicated by the dashed line. KCNN4 levels were
normalized to IL-4-treated cells (set to 1.0) and compared with and without
each inhibitor. (B) Summary of TRAM-34-sensitive KCa3.1 current densities
(pA/pF). NS309-evoked currents were measured at +80 mV in IL-4-treated
microglia, with or without a JAK inhibitor. InA,B, values are mean ± SEM for
the number of cultures or cells indicated, and differences from control cells
were determined using a 1-way ANOVA with Tukey’s post hoc test: 1 symbol
indicates p < 0.05; two symbols, p < 0.01. (C−E) Representative current
activation (left panels) and time courses (right panels) for three microglial
cells; each treated with a different JAK inhibitor. Currents were elicited by
repeated voltage ramps from –100 to +80 mV from a holding potential
of –70 mV, and each example shows superimposed currents in normal bath
solution (“1”), after bath application of 500 nM NS309 (“2”), and 1 μM
TRAM-34 in the continued presence of NS309 (blue trace, “3”).
and KCa3.1 current in alternatively activated microglia require
Ras/MEK/ERK signaling to AP-1, while the channel function also
requires PI3K.
MICROGLIAL MIGRATION IS INCREASED BY IL-4, AND REQUIRES KCa3.1
ACTIVITY, JAK3, Ras/MEK/ERK, and AP-1 SIGNALING
We ﬁrst corroborated our recent ﬁnding (Lively and Schlichter,
2013) that LPS decreases and IL-4 increases the migratory capac-
ity of rat primary microglia, and then we tested whether KCa3.1
is involved. The migration of LPS-treated cells was 42% ± 4%
(n = 3) that of unstimulated cells and was unaffected by
TRAM-34 (42% ± 4% of the unstimulated value; n = 3;
not illustrated). Then, based on the IL-4-evoked increases in
KCNN4 mRNA (Figure 1C) and KCa3.1 current (Figure 2),
we asked whether TRAM-34 affects the IL-4-mediated increase
in migration. TRAM-34 did not inhibit migration of control
(unstimulated) microglia, but fully inhibited the increased migra-
tory capacity of IL-4-treated cells (Figure 7A). IL-4 can act as
a mitogen (reviewed in Wills-Karp and Finkelman, 2008), so it
is important that the total cell density was not affected by IL-4
(or TRAM-34) over the 24 h test period (Figure 7B). As for the
increase in KCa3.1 current (Figure 3E), protein synthesis was nec-
essary for the enhanced migration; cycloheximide abolished the
increase in IL-4-treated cells but had no effect on unstimulated
microglia (Figure 7C). JAK3 was involved in the IL-4-mediated
increase in migration; it was abolished by the JAK2/3 inhibitor
(AG490) and the JAK3 inhibitor (tofacitinib), while the JAK2
inhibitor (TG101348) was ineffective (Figure 7D). The IL-4 medi-
ated increase in migration was abolished by the PI3K inhibitor
(wortmannin), the MEK inhibitor (PD98059), and the AP-1
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FIGURE 6 | Ras/MEK/ERK andAP-1 signaling are required for induction
of KCNN4 mRNA and KCa3.1 current in IL-4 treated microglia. (A–F) Rat
microglia were treated for 24 h with 20 ng/ml rat recombinant IL-4, without
(control) or with an inhibitor of a signaling molecule: 200 nM AS1517499 (for
STAT6), 100 nM wortmannin (for PI3K), 20 μM PD098059 (for MEK1/2), or
1 μM SR11302 (for AP-1). (A) IL-4-mediated induction of KCNN4 mRNA was
examined using quantitative real-time qRT-PCR. Control KCNN4 mRNA levels
in unstimulated microglia (no IL-4) are indicated by the dashed line. KCNN4
levels were normalized to IL-4-treated cells (set to 1.0) and compared with and
without each inhibitor. (B) Summary of TRAM-34-sensitive KCa3.1 current
densities (pA/pF) that were evoked by NS309 and measured at +80 mV in
IL-4-treated microglia with or without an inhibitor. InA,B, values are
mean ± SEM for the number of cultures or cells indicated, and differences
from control cells were determined using a 1-way ANOVA with Tukey’s post
hoc test: 1 symbol indicates p < 0.05; two symbols, p < 0.01; three symbols,
p < 0.001. (C–F) Representative current activation (left panels) and time
courses (right panels) for four microglial cells; each treated with a different
inhibitor. Currents were elicited by repeated voltage ramps from –100 to
+80 mV from a holding potential of –70 mV, and each example shows
superimposed currents in normal bath solution (“1”), after bath application of
500 nM NS309 (“2”), and 1 μMTRAM-34 in the continued presence of
NS309 (blue trace, “3”).
inhibitor (SR11302), but not affected by the STAT6 inhibitor
(AS1517499; Figure 7E). [An82%reductionwas also seenwith the
MEK inhibitor, U0126 (not shown).] Together, our results show
that the same signaling pathway (JAK3, PI3K, Ras/MEK/ERK,
AP-1) was involved in the IL-4-induced increase in KCa3.1 current
and migration.
DISCUSSION
Initially, it was thought that KCa3.1 channels were absent from
the CNS. However, KCNN4 transcripts or KCa3.1 protein have
recently been found in microglia (see below), oligodendrocytes,
reactive astrocytes (Bouhy et al., 2011), and some CNS neu-
rons (Kaushal et al., 2007; Bouhy et al., 2011; Engbers et al.,
2012). Importantly, KCa3.1 blockers have improved the out-
come in several rodent models of CNS damage. For instance,
edema, intracranial pressure, and lesion volume were reduced
in a rat model of traumatic brain injury (Mauler et al., 2004),
as was disability and pro-inﬂammatory chemokine and cytokine
expression in the spinal cord in a murine model of multi-
ple sclerosis (Reich et al., 2005). We reported that the KCa3.1
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FIGURE 7 |The IL-4 induced increase in microglial migration is
mediated through JAK3 and MEK signaling, and requires AP-1
activation, new protein synthesis, and KCa3.1 channel function.
(A,C–E) Rat microglia were seeded in TranswellTM chambers and left
unstimulated (control cells) or treated for 24 h with 20 ng/ml rat
recombinant IL-4.When used, each inhibitor was added immediately before
(Continued)
FIGURE 7 | Continued
adding IL-4. Cells were ﬁxed after 24 h, and microglia that had migrated to
the underside of each ﬁlter were counted in ﬁve random ﬁelds. (B) Cell
proliferation was analyzed using a CyQuant proliferation assay. Treatments
were: (A,B) the KCa3.1 channel blocker, 1 μMTRAM-34; (C) the protein
synthesis inhibitor, 10 nM cycloheximide (CHX); (D) 10 μM AG490 (JAK2/3
inhibitor), 10 nM tofacitinib (JAK3 inhibitor), 30 nMTG101348 (JAK2
inhibitor); (E) 200 nM AS1517499 (STAT6 inhibitor), 100 nM wortmannin
(PI3K inhibitor), 20 μM PD098059 (MEK1/2 inhibitor), 1 μM SR11302 (AP-1
inhibitor). Data are expressed as mean ± SEM, with the numbers of
individual cultures indicated. Note that a separate set of control cultures
was used for each experiment (control values indicated by dashed lines in
D,E). A 2-way ANOVA with Bonferroni’s post hoc test (A–C) or a 1-way
ANOVA with Tukey’s post hoc test (D,E) revealed differences (p < 0.001)
between unstimulated and IL-4-treated microglia (***) and the effects of
each antagonist (###).
blocker, TRAM-34, reduced neurodegeneration following optic
nerve damage (Kaushal et al., 2007), and reduced the loss of tis-
sue and neurons, and locomotor impairment after spinal cord
injury in the mouse (Bouhy et al., 2011). In a rat model of
transient ischemia, TRAM-34 reduced the number of activated
microglia/macrophages, reduced the infarct size, increased neu-
ron survival, and improved the neurological outcome (Chen et al.,
2011). The latter study showed increased KCa3.1 in activated
microglia/macrophages at the site of injury. Together, these in vivo
studies suggest that block of KCa3.1 in microglia reduces neuro-
toxicity by inhibiting the pro-inﬂammatory state, and they support
the therapeutic development of KCa3.1 blockers for CNSdisorders
that involve excessive inﬂammation. It is crucial to understand
KCa3.1 contributions to microglial functions in other activation
states.
Roles of KCa3.1 have previously been addressed using cul-
tured microglia and cell lines in vitro. Earlier studies with the
blockers, clotrimazole and charybdotoxin, showed inhibition
of superoxide production in primary rat microglia (Khanna
et al., 2001), lysophosphatidic acid-induced migration of BV-2
cells (murine microglia cell line; Schilling et al., 2004b), and
lysophosphatidylcholine-induced secretion of IL-1β fromprimary
murine microglia and BV-2 cells (Stock et al., 2006). However,
these blockers are not perfectly selective for KCa3.1; e.g., charyb-
dotoxin blocks other K+ channels, including Kv1.3 and large-
conductance Ca2+-activated (BK) channels that can contribute
to microglial functions. Kv1.3 contributes to proliferation, the res-
piratory burst, and neurotoxicity of rat microglia (Schlichter et al.,
1996; Kotecha and Schlichter, 1999; Khanna et al., 2001; Fordyce
et al., 2005), and BK contributes to microglia-mediated neuro-
pathic pain (Hayashi et al., 2011). More recent studies often exploit
TRAM-34, which is KCa3.1 selective at 1 μM (Wulff and Zhorov,
2008). In ratmicroglia, TRAM-34 reducedUTP-stimulatedmigra-
tion (Ferreira and Schlichter, 2013), and the p38MAPK activation,
production of nitric oxide, and neurotoxicity that were evoked
by lipopolysaccharide-induced classical activation (Kaushal et al.,
2007). In primary murine microglia, TRAM-34 reduced neuro-
toxicity induced by Aβ oligomers (Maezawa et al., 2011), and their
chemotactic activity andphagocytosis in response to glioblastoma-
conditioned medium (D’Alessandro et al., 2013). These studies
focused on pro-inﬂammatory (classical) activation but migra-
tion, for example, is also important in the healthy CNS. Here, we
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provide the ﬁrst evidence that KCa3.1 contributes to the enhanced
migratory capacity of alternative-activated microglia.
Supporting the pharmacological evidence for roles of KCa3.1
channels in rodent microglia, KCNN4 transcripts are expressed
in primary microglia from rats (Khanna et al., 2001; Kaushal
et al., 2007) and mice (Bouhy et al., 2011; Dolga et al., 2012),
and KCa3.1 protein is present in activated microglia/macrophages
in vivo (Kaushal et al., 2007; Chen et al., 2011). Surprisingly,
the presence of a KCa3.1 current has been rarely reported for
primary microglial cells. In comparing our results with the lit-
erature, we will consider whether this discrepancy reﬂects the
microglial activation state, differences between primary cells and
cell lines, experimental differences or the species. (i) Alternative
activation is thought to shift microglia from a pro-inﬂammatory
state to a resolving state that facilitates repair (Sica and Man-
tovani, 2012). Our results suggest that KCa3.1 is expressed in
microglia in diverse activation states. Previously, we only occasion-
ally detected a small-amplitude KCa3.1 current in unstimulated
rat microglia (Khanna et al., 2001; Kaushal et al., 2007). Here,
we detected a KCa3.1 current in 6/19 unstimulated rat microglia
but the amplitude was small (0.7–1.7 pA/pF). These cells were
similar to resting neonatal microglia in being highly migratory
(Lively and Schlichter, 2013) and phagocytic (Sivagnanam et al.,
2010), and were similar to resting adult microglia in having very
low expression of numerous activation markers. These included
low expression of the classical-activation markers, activated p38
MAPK and NFκB (Kaushal et al., 2007; Schlichter et al., 2010),
IL-1β, TNFα, iNOS, IL-10, BDNF (Sivagnanam et al., 2010; Liu
et al., 2013; Lively and Schlichter, 2013), and the alternative acti-
vation markers, MRC1, Arg1, and CD163 (Liu et al., 2013; Lively
and Schlichter, 2013). We previously found that KCNN4 mRNA
was not affected in classical-activated primary microglia from
rats (Kaushal et al., 2007) and mice (Bouhy et al., 2011) but we
did not examine the currents. We now show that with IL-4-
mediated alternative activation, KCNN4 transcripts and KCa3.1
currents were dramatically up-regulated such that 17/18 cells had
a large current (15–39 pA/pF). The current was induced within
1 day and sustained until at least 6 days, which was the longest
time tested. (ii) There are apparent discrepancies in reported
experimental conditions required to activate the KCa3.1 current
in primary microglia and cell lines. For cloned KCa3.1 chan-
nels and the native channels in most cell types, the EC50 value
for activation by Ca2+ is below 1 μM (Jensen et al., 2001; Wei
et al., 2005; Wulff and Zhorov, 2008). Whole-cell recordings with
1 μM intracellular Ca2+evoked KCa3.1 currents in the murine
BV-2 microglial cell line (Schilling et al., 2002, 2004a,b; Stock
et al., 2006) but not in the murine C8-B4 cell line, even when
the channel activator, DC-EBIO, was present (Moussaud et al.,
2009). For the rat MLS-9 microglial cell line, we routinely activate
a large TRAM-34-sensitive KCa3.1 current but only with high
internal Ca2+ (EC50 ∼ 7 μM) or lower Ca2+ and a channel
activator (e.g., riluzole, UTP; Ferreira and Schlichter, 2013; Liu
et al., 2013). Similarly, in the present study, current activation in
alternative-activated microglia required 1 μM intracellular Ca2+
and a KCa channel activator. Riluzole, 1-EBIO and NS309 are
thought to act by increasing the Ca2+ sensitivity by up to an order
of magnitude (Pedersen et al., 1999; Syme et al., 2000; Pedarzani
et al., 2001). While mechanisms underlying the low Ca2+ sen-
sitivity of the channels in rat microglia are unknown, they will
be important to investigate in future and might contribute to a
failure to record KCa3.1 currents in other microglia. (iii) There
might be species differences in expression of KCa currents in
primary microglia but this has not been directly assessed and
there are also experimental differences in the studies. In whole-
cell recordings with ∼1 μM intracellular Ca2+, microglia from
NMRI mice had charybdotoxin-sensitive KCa3.1-like currents of
∼200 to >1000 pA (Eder et al., 1997; Schilling et al., 2002) but
their prevalence and mean amplitude were not reported. The
microglial activation state was not determined; however, the cells
had been cultured with macrophage colony stimulating factor for
1–2 weeks, and astrocyte-conditioned medium for a few days.
In primary microglia from C57BL6 mice, a TRAM-34-sensitive
KCa3.1 current was activated in 11/17 cells, and was 50–100 pA in
the recordings shown (Maezawa et al., 2011). Most in vitro studies
use cultured neonatal microglia, and there is some indication of
differences in KCa currents related to cell culturing and animal
age. No KCa3.1 currents were seen in microglia in acute brain
slices from juvenile mice but a BK current was reported after
the slices were cultured (Schilling and Eder, 2007). Discrepan-
cies in reports of BK currents further support the possibility that
both KCa currents are species-dependent or adversely affected by
experimental conditions. For instance, a BK current was not seen
in rat microglia, even after damage caused by facial nerve axotomy
(Boucsein et al., 2000); whereas, it was present in acute brain slices
frommice (Menteyne et al., 2009; Hayashi et al., 2011), and human
epileptic patients (Bordey and Spencer, 2003). Surprisingly, in the
latter two studies BK was activated without elevating intracellular
Ca2+. Together, these results highlight the need for future studies
to directly compare expression and roles of KCa currents in pri-
mary microglia of different species under identical experimental
conditions.
In addressing the signaling pathways responsible for increas-
ing KCNN4 expression and KCa3.1 currents in microglia, our
results have broader implications for cells that express and use
KCa3.1 or IL-4 signaling. Following IL-4 binding to the IL-
4Rα subchain, changes in gene expression can occur through
STAT6 or IRS2-PI3K pathways, and less commonly by IRS2-
Grb2 and the Ras/MEK/ERK pathway (see Figure 4). There is
emerging evidence that Ras/MEK/ERK signaling is important for
alternative activation of microglia (Zhou et al., 2012). Activated
ERK1/2 translocates to the nucleus and activates transcription
through the c-Fos/c-Jun heterodimer,AP-1 (Park and Levitt, 1993;
Marais and Marshall, 1996). We found that IL-4 binding to the
Type I receptor was responsible for increasing KCNN4 mRNA
and KCa3.1 current. The increase in current required protein
synthesis and was mediated by JAK3, the Ras/MEK/ERK path-
way and AP-1. The same receptor and signaling pathway was
involved in increasing the migratory capacity and its KCa3.1
dependence in alternative-activated microglia. There is some liter-
ature on pathways regulating KCa3.1 expression but connections
between the channel, IL-4 and AP-1 have not previously been
addressed. Ras/MEK/ERK signaling up-regulates KCa3.1 in sev-
eral cell types (Pena et al., 2000; Grgic et al., 2005, 2009; Si et al.,
2006). Promoter analysis of the KCNN4 gene identiﬁed sites
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for AP-1 (and Ikaros-2), and increased expression of KCa3.1 in
mitogen-activated T lymphocytes is especially dependent on AP-1
(Ghanshani et al., 2000).
Two observations that warrant further study are that, in IL-
4-treated microglia, inhibiting either STAT6 or PI3K increased
KCNN4 mRNA expression, but inhibiting PI3K decreased the
current. While speculative, two possibilities seem reasonable. (i)
PI3K can exert post-translational regulation of KCa3.1 current;
i.e., inhibiting PI3K with wortmannin reduced the current from
cloned humanKCa3.1 channels expressed inCHOcells, and native
channels in activated human CD24+ T lymphocytes (Srivastava
et al., 2006). (ii) Transcription regulation might be subject to neg-
ative feedback, because potential cross-talk mechanisms exist in
IL-4 receptor signaling pathways (reviewed in Nelms et al., 1999).
JAK1−3 molecules can be inhibited by their interaction with SH2-
domain proteins following STAT6 activation; for example, by
cytokine-induced SH2 (CIS) and suppressor of cytokine signaling
3 (SOCS-3). After IL-4 receptor engagement, Ras can be inacti-
vated by recruitment of a Ras GTPase activating protein by the
p62dok family protein, FRIP (IL-4 receptor interacting protein).
If either JAK3 or Ras is inhibited, reduced KCNN4 expression is
anticipated.
Microglial activation is multi-faceted, and will depend on the
type of stimulus, time after stimulation and factors in the local
milieu (Stout, 2010; Luo andChen, 2012). Our ﬁnding that KCa3.1
expression and contributions are regulated by the microglial acti-
vation statewill have implications for targeting theKCa3.1 channel
to modulate CNS inﬂammation. The increased migratory capac-
ity and contribution of KCa3.1 in alternative-activated microglia
is intriguing. Migration is a crucial property of microglia whether
in the healthy brain during development or after damage, but the
consequences will depend on the function of the cells at the target
site. Microglia normally migrate within the developing CNS to
help shape brain architecture and, to minimize bystander damage,
it would be beneﬁcial if they are in a non-damaging state while
migrating. After CNS damage, microglia migrate to injury sites
and again, a non-cytotoxic state would be beneﬁcial. If KCa3.1
blockers inhibit migration of only alternative-activated microglia,
as our results suggest, they might allow these cells to remain longer
at the damage site to resolve the pro-inﬂammatory state and pro-
mote repair. This work also suggests that the timing of applying
KCa3.1 blockers after CNS damage will be important in order to
allow beneﬁcial contributions of microglia.
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